July 30 (Reuters) - U.S. medical device maker Stryker

on Thursday beat Wall Street estimates for

second-quarter results, aided by strong demand for its implants

and devices used in complex procedures ranging from spinal to

orthopedic surgeries.

However, the company's shares fell 9% in extended trading

after the Michigan-based firm missed analysts' estimates for

medical surgery and neurotechnology sales in the quarter, its

largest revenue-generating segment.

Here are the details:

* The company, which makes joint replacements and medical

implants used to repair broken bones, narrowed its forecast for

adjusted annual profit to between $14.95 and $15.10 per share,

from its prior range of $14.90 to $15.10 per share.

* Stryker's rivals in the orthopedics market include Zimmer

Biomet ( ZBH ) and healthcare conglomerate Johnson & Johnson ( JNJ )

, where the companies jostle for market share across

multiple segments such as hip and knee replacements, trauma and

sports medicine.

* Sales at Stryker's medical surgery and neurotechnology

unit, rose 9.7% to $3.6 billion in the reported quarter, but

missed analysts' estimates of $3.72 billion, according to data

compiled by LSEG.

* The orthopedics segment saw a 9.1% increase in sales to

$3.0 billion, which beat analysts' expectations of $2.72

billion.

* The company reported total revenue of $6.6 billion for the

quarter, above analysts' expectations of $6.58 billion.

* Stryker earned $3.69 per share for the quarter on an

adjusted basis, surpassing estimates of $3.49 apiece.